Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) Article

Full Text via DOI: 10.1016/j.amjcard.2012.11.031 PMID: 23290925 Web of Science: 000315666600023

Cited authors

  • DiNicolantonio, James J.; Lavie, Carl J.; Fares, Hassan; Menezes, Arthur R.; O'Keefe, James H.

Abstract

  • Because carvedilol is a unique vasodilating beta blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings. A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF. Compared to beta(1)-selective BBs used in HF (8 trials, n = 4,563), carvedilol significantly reduced all-cause mortality (risk ratio 0.85, 95% confidence interval 0.78 to 0.93, p = 0.0006). In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16). In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients. Additionally, carvedilol significantly reduced all-cause mortality compared with beta(1)-selective BBs in AMI patients using the fixed-effects model but not using the random-effects model. (c) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:765-769)

Publication date

  • 2013

Published in

International Standard Serial Number (ISSN)

  • 0002-9149

Start page

  • 765

End page

  • 769

Volume

  • 111

Issue

  • 5